VRTX VERTEX PHARMACEUTICALS INC Management Changes 8-K Filing 2025 - Management Changes Vertex Pharmaceuticals reported its financial results for the year ending December 31, 2024, and announced the retirement of COO Stuart A. Arbuckle, effective July 1, 2025, while appointing Charles F. Wagner, Jr. as COO and Duncan J. McKechnie as Chief Commercial Officer, both effective on the same date.Get access to all SEC 8-K filings of the VERTEX PHARMACEUTICALS INC